2024-01-25 17:30:32 ET More on PTC Therapeutics PTC Therapeutics, Inc. (PTCT) Q3 2023 Earnings Call Transcript PTC Therapeutics says total unaudited FY23 net revenue was about $946M PTC Therapeutics issues EU, US regulatory updates on Translarna Seeking Alpha...
Rhythm Pharmaceuticals ( NASDAQ: RYTM ) is trading 21% higher after the company posted narrower-than-expected Q2 loss, helped by sales of its genetic disorder drug, Imcivree and license revenue. The company posted Q2 GAAP EPS of -$0.89, which beat estimate...
GlaxoSmithKline (NYSE:GSK) is scheduled to announce Q3 earnings results on Wednesday, October 27th, before market open. The consensus EPS Estimate is $0.81 (+224.0% Y/Y) and the consensus Revenue Estimate is $11.96B (+38.3% Y/Y). Over the last 2 years, GSK has beaten EPS estimates 88% of the ...
With Labor Day marking the unofficial end of summer, September looks to be a busy month for events impacting pharmaceutical and biotechnology companies. Here's a look at what events to look forward to this month that could impact pharma and biotech stocks. Sept. 3: FDA Cellular, Tissue,...
Bristol Myers Squibb (BMY) announces that the EMA's Committee for Medicinal Products for Human Use ((CHMP)) has recommended granting Conditional Marketing Authorization for Abecma (idecabtagene vicleucel; ide-cel), the company’s BCMA-directed chimeric antigen receptor ((CAR)) T cell im...
Analysis focus: Omeros Today we will discuss Omeros (NASDAQ: OMER ), which has surged on the back of an update for its approved product Omidria. We discussed the pass through situation with Omidria in an article late last year. As we noted, Omidria was expected to lose its separate ...
Analysis of top Seeking Alpha coverage: Clovis Oncology Today we will discuss Clovis Oncology ( CLVS ). Clovis Oncology have had a good run this week, gaining more than 11%. The stock though still remains down more than 21% in the last six months and well-off its 52-week high of $99.45. T...
Analysis of top Seeking Alpha coverage: Portola Pharmaceuticals Today we will discuss Portola Pharmaceuticals ( PTLA ), which came out with some mixed news. PTLA shares were down sharply at the time of writing this note. Portola reported that the European Medicines Agency’s ((EM...
Today we will discuss the Ad Com's vote against Lipocine's ( LPCN ) TLANDO. The news sparked a huge sell-off in LPCN on Wednesday. Few days before the Ad Com, we had written a note on LPCN, highlighting that it is a binary event. TLANDO had been rejected by the FDA in 2016, which pushed LPCN...